Evidence map›Paper›PMID 38234210›Full record

ArticleCancer medicine2024

Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients.

Yasumasa Shimasaki, Hiroaki Miyoshi, Keisuke Kawamoto, Noriaki Yoshida, Tatsuzo Mishina, Kazutaka Nakashima, Teppei Imamoto, Takeshi Sugio, Eriko Yanagida, Takeharu Kato and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 1 country.

Yasumasa ShimasakiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Hiroaki MiyoshiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID 0000-0002-2356-3725
Keisuke KawamotoDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Noriaki YoshidaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Tatsuzo MishinaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kazutaka NakashimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Teppei ImamotoDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Takeshi SugioDepartment of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Eriko YanagidaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Takeharu KatoDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kyohei YamadaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Mai TakeuchiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Takaharu SuzukiDepartment of Hematology, Endocrinology, and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Mayuko MoritsuboDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID 0000-0002-3382-0473
Takuya FurutaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-2954-5691
Jun TakizawaDepartment of Hematology, Endocrinology, and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Koji KatoDepartment of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Junji SuzumiyaDepartment of Hematology, Kohga Hospital, Yaizu, Japan.
Ritsuro SuzukiDepartment of Hematology, Shimane University Hospital, Izumo, Japan.
Koichi OhshimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kurume University · JPKyushu University · JPNagasaki University · JPNiigata University · JPKoga Hospital · JPShimane University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimPeripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a heterogeneous disease that can be classified into the PTCL-TBX21 and PTCL-GATA3 subtypes.

methodsIn this study, we compared the clinicopathological features of PTCL-NOS in a Japanese cohort, classified using an IHC algorithm.

resultsOne hundred patients with PTCL-NOS were categorized as having PTCL-TBX21 (n = 55), PTCL-GATA3 (n = 24), or PTCL-unclassified (n = 21). When comparing PTCL-TBX21 and PTCL-GATA3, PTCL-TBX21 showed significantly lower CD4 positivity (p = 0.047), lower counts of high endothelial venules (p = 0.032), and a tendency for a better response to initial treatment (p = 0.088). Gene expression analysis using the nCounter system showed higher expression of tumor immunity-related genes, such as PD-L1, LAG3, and IDO1, in PTCL-TBX21 than in PTCL-GATA3. PTCL-GATA3 had significantly worse overall survival (OS) than those with PTCL-TBX21 (p = 0.047), although a similar tendency was observed for progression-free survival (PFS) (p = 0.064). PTCL-GATA3 was a prognostic factor for OS in univariate analysis (HR 2.02; 95% CI, 1.09-3.77; p = 0.027), although multivariate analysis did not show significance (HR 2.07; 95% CI, 0.93-4.61; p = 0.074). In the PFS analysis, PTCL-GATA3 was an independent prognostic factor by univariate analysis (HR 1.96; 95% CI, 1.08-3.56; p = 0.027) and multivariate analysis (HR 2.34; 95% CI, 1.07-5.11; p = 0.032).

conclusionThe classification of PTCL-NOS into PTCL-TBX21 and PTCL-GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.

Indexed as

AlgorithmsLymphoma, T-Cell, PeripheralGATA3 Transcription FactorGene Expression ProfilingHumansImmune Checkpoint InhibitorsJapanGATA3 protein, humanGATA3 Transcription FactorImmune Checkpoint Inhibitorspathologyperipheral T-cell lymphoma not otherwise specifiedPTCL-GATA3PTCL-TBX21

Identifiers

PMID38234210
PMCPMC10905534
OpenAlexW4390977850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.